ArticleFrontiers in microbiology2018
Novel Combinations of Agents Targeting Translation That Synergistically Inhibit Fungal Pathogens.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Experimental Evolution of PathogenicMicroorganisms · 2026Review
- Cinchona-based liquid formulation exhibits antifungal activity through Tryptophan starvation and disruption of mitochondrial respiration in Rhizoctonia Solani.Scientific reports · 2025Article
- Translation Inhibition by Rocaglamide A Enhances Susceptibility of Yeasts to Caspofungin.bioRxiv : the preprint server for biology · 2025Article
- Ire1 inhibitors attenuateFrontiers in microbiology · 2025Article
- Effect of Escin Alone or in Combination with Antifungal Agents on ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Impaired amino acid uptake leads to global metabolic imbalance of Candida albicans biofilms.NPJ biofilms and microbiomes · 2022Article
- Pharmacokinetic profile of sarcin and thionin from Aspergillus giganteus and in vitro validation against human fungal pathogen.Bioscience reports · 2022Article
- An Adjuvant-Based Approach Enables the Use of DominantmSphere · 2022Article
- Discovery of Natural Products With Antifungal Potential Through Combinatorial Synergy.Frontiers in microbiology · 2022Article
- Evolving challenges and strategies for fungal control in the food supply chain.Fungal biology reviews · 2021Review
- Potentiated inhibition of Trichoderma virens and other environmental fungi by new biocide combinations.Applied microbiology and biotechnology · 2021Article
- Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020Article
- Combination of Miconazole and Domiphen Bromide Is Fungicidal against Biofilms of ResistantAntimicrobial agents and chemotherapy · 2020Article
- Extreme Osmotolerance and Halotolerance in Food-Relevant Yeasts and the Role of Glycerol-Dependent Cell Individuality.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A range of fungicides or antifungals are currently deployed to control fungi in agriculture or medicine, but resistance to current agents is growing so new approaches and molecular targets are urgently needed. Recently, different aminoglycoside antibiotics combined with particular transport inhibitors were found to produce strong, synergistic growth-inhibition of fungi, by synergistically increasing the error rate of mRNA translation. Here, focusing on translation fidelity as a novel target for combinatorial antifungal treatment, we tested the hypothesis that alternative combinations of agents known to affect the availability of functional amino acids would synergistically inhibit growth of major fungal pathogens. We screened 172 novel combinations against three phytopathogens (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.